Search results
Results from the WOW.Com Content Network
454 Life Sciences was a biotechnology company based in Branford, Connecticut that specialized in high-throughput DNA sequencing.It was acquired by Roche in 2007 and shut down by Roche in 2013 when its technology became noncompetitive, although production continued until mid-2016.
The Institute is the majority stakeholder for ACI, [6] [7] where over 40% of yearly profits from the company are distributed to the Institute as dividends. Since 2000, over $1.8 billion in dividends have powered research and discovery, untethering scientists from procuring outside funding and allowing researchers to pursue bold research questions.
In March 2013, Complete Genomics was acquired by BGI Group. [17] After the acquisition, Complete Genomics moved to San Jose, and in June 2018 became part of MGI. [18] [19] The acquisition was the one of the outcomes of $1.5 billion 'collaborative funds' i.e., '10 years loan' which was initially provided by China Development Bank to acquire all 128 of Illumina, Inc.'s newest and fastest next ...
In 2002, BGI sequenced the rice genome, which was a cover story in the journal Science. In 2003, BGI decoded the SARS virus genome and created a kit for detection of the virus. [19] In 2003, the Chinese Academy of Sciences founded the Beijing Institute of Genomics in cooperation with BGI, with Yang Huanming as its first director.
Broad Institute (Massachusetts Institute of Technology and Harvard University) Dana–Farber Cancer Institute; Whitehead Institute for Biomedical Research (Massachusetts Institute of Technology) Missouri. McDonnell Genome Institute (Washington University in St. Louis) New Mexico. National Center for Genome Resources; New York. Cold Spring ...
From August 2008 to December 2012, if you bought shares in companies when Frederick B. “Bart” Harvey III joined the board, and sold them when he left, you would have a -95.7 percent return on your investment, compared to a 13.2 percent return from the S&P 500.
Researchers from The Institute of Cancer Research in London have developed a new test that can predict colorectal cancer risk in people with IBD with more than 90% accuracy.
In 1990, UCSF sued Genentech for $400 million in compensation for alleged theft of technology developed at the university and covered by a 1982 patent. [citation needed] Genentech claimed that they developed Protropin (recombinant somatotropin/human growth hormone), independently of UCSF. A jury ruled that the university's patent was valid in ...